Alivus Life Sciences Limited has informed the Exchange about Transcript of Earnings Call.
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alivus Life Sciences reported FY26 revenue of INR 2,552 crores, up 6.9% YoY, with EBITDA of INR 858 crores, growing 19.6%. EBITDA margin expanded to 33.6%, the highest in company history, up 360 basis points YoY, driven by favorable product mix and operational efficiencies. The non-GPL business now contributes 71% of revenue (up from 59% in FY22), growing 13% YoY, reducing dependence on the GPL segment. The company added 11 new products (176 total molecules) and 49 new customers (~900 total). CDMO business recovered with 18% growth. Management guided for maintaining EBITDA margins in the 30-32% range going forward. Cash position stands at INR 782 crores with net debt-free status. Solapur Phase 1 is on track for Q2 FY27, and FY27 capex of INR 540 crores will be funded from internal accruals.
The company's margin expansion and shift toward higher-margin non-GPL business signals improved earnings quality. The net debt-free position with INR 782 crores cash provides strong balance sheet flexibility for growth investments, though near-term margins may face headwinds from geopolitical factors.